In Vivo CAR-T Cell Therapy: Technology Platforms, Clinical Progress, and Strategic Landscape (2021–July 2026)

Introduction

Chimeric antigen receptor T-cell (CAR-T) therapy has fundamentally reshaped the treatment of hematologic malignancies, with six FDA-approved autologous products now in clinical practice. Yet the conventional ex vivo manufacturing model—requiring leukapheresis, viral transduction, selective expansion, and reinfusion over several weeks—imposes enormous cost (typically $450,000–$500,000 per infusion, with total care costs exceeding $1 million in complicated cases), logistical complexity, and access barriers that confine therapy to specialized centers. In vivo CAR-T engineering offers a fundamentally different paradigm: rather than manufacturing CAR-expressing T cells outside the body, genetic instructions are delivered directly to endogenous T cells within the patient, generating CAR-T effectors in situ. This review synthesizes evidence from January 2021 through July 24, 2026, covering delivery platforms, translational progress, competitive dynamics, and strategic implications for medical professionals 18.

Technology Platforms

The field has converged on two primary delivery categories—viral vectors and non-viral nanoparticle systems—each with distinct profiles for persistence, targeting selectivity, manufacturability, and safety.

Lentiviral (LV) vectors remain the most clinically advanced in vivo modality. Engineered LV particles integrate CAR-encoding DNA into the host T-cell genome, enabling durable expression from a single administration. To achieve T-cell selectivity, surface-displayed anti-CD3, anti-CD4, or anti-CD8 single-chain variable fragments (scFv) direct vector uptake; some platforms simultaneously deliver co-stimulatory activation signals to promote T-cell priming in a lymphoreplete environment, circumventing the need for preparative lymphodepletion. Umoja Biopharma's VivoVec platform and Kelonia's in vivo gene placement system (iGPS) exemplify this approach. The principal safety concern is insertional mutagenesis, though third-generation LV design substantially mitigates—but does not eliminate—this risk 18.

Adeno-associated viral (AAV) vectors offer episomal persistence without genomic integration, favorable immunogenicity, and established GMP (Good Manufacturing Practice) manufacturing. However, AAV's limited packaging capacity (~4.7 kb) constrains CAR construct complexity, and its natural tropism requires antibody pseudotyping for T-cell selectivity. A 2021 landmark preclinical study demonstrated that a single intravenous infusion of AAV encoding an anti-CD4 CAR generated detectable CAR expression in 9% of CD45+ cells by 48 hours, achieved complete tumor remission in four of six treated humanized mice, and produced robust Th1 cytokines (TNF-α, IL-2, IFN-γ), validating the in vivo concept. Clinical translation of AAV has been slower than lentiviral approaches in the retrieved evidence 2.

Lipid nanoparticles (LNPs) delivering mRNA represent the most rapidly expanding non-viral platform, leveraging manufacturing infrastructure and regulatory precedent from COVID-19 vaccines. mRNA-encoded CARs typically persist 7–14 days, eliminating integration risk and enabling dose titration and repeat administration. Antibody-conjugated LNPs (e.g., anti-CD3, anti-CD8) target specific T-cell subsets, reducing off-target transfection. Circular RNA-LNP systems—developed by companies including Orna Therapeutics and Orbital Therapeutics—extend expression to 14–21 days due to slower RNA degradation, offering semi-durable activity without genomic integration 389.

Gene-writing and non-viral DNA integration systems, exemplified by Tessera Therapeutics' Gene Writers platform supported by a $41.3 million ARPA-H EMBODY program award (September 2025), aim to combine non-viral manufacturability with durable CAR expression via precise genomic insertion. This class remains primarily preclinical as of July 2026 16.

Table 1. In Vivo CAR-T Delivery Platform Comparison

Clinical and Translational Progress

As of July 2026, in vivo CAR-T has transitioned from preclinical proof-of-concept to human trials across hematologic oncology, multiple myeloma, and autoimmune disease. The most consequential human datasets in the retrieved evidence come from lentiviral platforms 1112.

Kelonia Therapeutics' KLN-1010 (anti-B-cell maturation antigen [BCMA], iGPS lentiviral platform) presented Phase 1 data from the inMMyCAR trial in relapsed/refractory multiple myeloma at the American Society of Hematology (ASH) 2025 Annual Meeting. Among the first four treated patients, lymphodepletion was not required—a major operational advantage. CAR-positive T cells peaked at approximately day 15 (representing 22–85% of CD3+ cells), with memory phenotype enrichment. All four patients achieved measurable residual disease (MRD)-negative status within one month at 10⁻⁶ sensitivity. Cytokine release syndrome (CRS) was grade 1–2 in three of four patients; one transient grade 4 neutropenia (margination) was observed; no immune effector cell-associated neurotoxicity syndrome (ICANS) was reported 11.

Legend Biotech's LB2501 (CD19/CD20 dual-target in vivo lentiviral CAR-T) reported first-in-human data at the European Hematology Association (EHA) 2026 meeting for relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). At the higher dose cohort, the objective response rate (ORR) was 100%, with a complete response (CR) rate of 83.3%; all responses were ongoing at data cutoff. No dose-limiting toxicities, serious adverse events, or neurotoxicity were disclosed 12.

Umoja Biopharma holds two lentiviral VivoVec programs in U.S. human trials: UB-VV111 (CD19-directed, Phase 1 with FDA IND clearance in 2024, Fast Track designation in 2025; no efficacy data disclosed in retrieved materials) and UB-VV400 (CD22-directed, Phase 1/2 VIBRANT-1; IND cleared July 2026, first patient anticipated Q3 2026) 417.

Genocury Biopharmaceutical (China) disclosed the first published clinical result of in vivo CAR-T in September 2025: a patient with high-burden relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieved CR one month after administration with no grade ≥2 CRS or ICANS, under an investigator-initiated trial (IIT) at Zhengzhou University's First Affiliated Hospital. An NMPA IND-approved program, SYS6055 (SinoMab/Sihuan Pharmaceutical, CD19-directed lentiviral), has also entered Phase 1 in China 78.

For non-oncology applications, AbbVie's CPTX2309 (via Capstan Therapeutics acquisition; targeted LNP-mRNA, CD19-directed) entered Phase 1 for B-cell-mediated autoimmune diseases including systemic lupus erythematosus (SLE) and rheumatoid arthritis. A 2026 review references the first global clinical study of LNP-based in vivo CAR-T for SLE, though program name and sponsor were not fully disclosed in retrieved materials 57. Create Medicines' MT-304 (RNA-LNP, HER2-directed) dosed its first patient in a Phase 1/2 study for HER2-positive solid tumors in 2026 15.

Table 2. Key In Vivo CAR-T Clinical and Pipeline Programs (as of July 24, 2026)

DLT: dose-limiting toxicity; SAE: serious adverse event; RA: rheumatoid arthritis; B-NHL: B-cell non-Hodgkin lymphoma; B-ALL: B-cell acute lymphoblastic leukemia

Competitive Landscape

Approximately 38 companies and multiple academic groups globally are developing in vivo CAR-T platforms as of July 2026 20. The U.S. leads in clinical translation and strategic transaction volume. Europe contributes platform innovation, particularly through EsoBiotec (Belgium, ENaBL lentiviral platform, acquired by AstraZeneca) and AAVivo. China has emerged as a significant hub, with NMPA approval of IND applications and at least three active clinical programs. CD19 is the dominant disclosed target (37.3% of programs), followed by BCMA (10.2%), with emerging solid tumor programs (HER2, TROP2, CLDN18.1) still primarily preclinical 2021.

Deal-Making and Investment Signals

The most striking strategic signal of the period was a cluster of four pharma acquisitions totaling approximately $5.9 billion in 12 months (March 2025–February 2026), reflecting high conviction that in vivo CAR-T represents a tractable modality rather than speculative concept 21.

Table 3. Major In Vivo CAR-T Transactions (2021–July 2026)

The pattern reveals a bifurcated strategic landscape: lentiviral platforms attracted the largest single transaction values (Lilly-Kelonia at $7.0 billion) due to their clinical de-risking and durable expression profile, while RNA/LNP platforms attracted sustained venture capital and mid-sized pharma acquisitions for their manufacturability and reversibility advantages 21. Two of four major acquisitions converge on CD19-directed autoimmune disease as the lead indication, suggesting pharma confidence in the target while hedging across delivery mechanisms 21.

Medical and Strategic Implications

In vivo CAR-T directly addresses the principal operational barriers limiting ex vivo therapy: manufacturing lead time (weeks to months reduced to a single infusion), per-patient manufacturing cost (potentially reduced from $450,000–$500,000 to biologics-comparable levels), scalability (off-the-shelf availability), and access (potential deployment beyond tertiary centers without apheresis infrastructure). KLN-1010's Phase 1 data confirming CAR-T expansion without lymphodepletion is particularly clinically significant, as preparative chemotherapy adds toxicity burden and restricts eligibility 11.

However, critical unresolved risks must be acknowledged. Delivery specificity remains imperfect: even antibody-conjugated LNPs and receptor-targeted lentiviral particles may transduce non-T cells, including hematopoietic stem cells or—theoretically—germline cells, with incompletely characterized long-term consequences 8. CRS has been observed in early human data, though generally grade 1–2; larger cohorts and longer follow-up are essential. Insertional mutagenesis from lentiviral integration carries a theoretical long-term cancer risk requiring multi-year surveillance. Immunogenicity from repeated LNP dosing or viral vector re-exposure may limit efficacy in repeat-dose regimens 89. Regulatory pathways remain nascent; while FDA IND clearance for UB-VV400 (July 2026) and NMPA approvals in China signal institutional willingness to advance the field, no in vivo CAR-T product has received marketing authorization anywhere as of July 24, 2026. Cross-program efficacy comparisons are premature given heterogeneous patient populations, dose levels, and short follow-up durations.

Looking ahead to 2026–2031, clinical inflection points include Phase 2 efficacy readouts from lentiviral programs (EsoBiotec, Umoja, Legend) and LNP-mRNA programs (AbbVie/Capstan, Create Medicines) in both oncology and autoimmune disease, anticipated in 2027–2028. First regulatory submissions may follow in 2027–2028, with approvals plausible by 2029–2030 if Phase 2 data are compelling. Solid-tumor expansion remains a longer-term priority; immunosuppressive tumor microenvironments and CAR-T trafficking limitations are barriers that in vivo approaches may partially but not fully mitigate compared to ex vivo products 1821.

For medical professionals, in vivo CAR-T warrants close monitoring as a potentially practice-changing modality. The convergence of first-in-human efficacy signals, major pharma strategic investment, and regulatory advancement through 2026 represents genuine progress—but durable remission data, long-term safety surveillance, and real-world cost validation remain essential prerequisites for broad clinical adoption.